Skip to content

Retrospective, Non-interventional Clinical Investigation of the Safety and Performance of 640AD Monofocal Intraocular Lens

Retrospective, Non-interventional Clinical Investigation of the Safety and Performance of 640AD Monofocal Intraocular Lens

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06578910
Enrollment
80
Registered
2024-08-30
Start date
2023-05-23
Completion date
2024-04-25
Last updated
2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract, Pseudophakia

Keywords

Intraocular lens, Ametropia - correction, Presbyopia- correction

Brief summary

Medicontur hydrophilic posterior chamber monofocal intraocular lens (IOL) is indicated to improve vision at far distance in adults with cataract and/or ametropia (hyperopia, myopia), secondarily to removal of the crystalline lens. The intraocular lens is intended to be surgically implanted into the eye with the purpose of restoring optical function in the aphakic eye to provide an optical system with high predictability of the precalculated dioptric power. The study will be performed partially as a retrospective study with patients enrolled who had been implanted with 640AD IOLs mono- or binocularly between December 2021 - December 2022. Data from five visits will be collected: * Baseline preoperative (maximum 30 days prior to surgery)- retrospective * IOL implantation Day 0 - retrospective * Postoperative visit at Day 1 (+/- 0 days) - retrospective * Postoperative visit at 1 month (+/- 2 weeks) - retrospective * Postoperative visit at 12 months (+/- 3 months) - consent and prospective visit

Interventions

DIAGNOSTIC_TESTStandard of care

12 months after the IOL implantation: measurement of intraocular pressure, slitlamp and fundus examination, visual acuity, manifest refraction.

VFQ- 25 (Visual Function Questionnare) to be completed during 12 month visit.

Sponsors

Medicontur Medical Engineering Ltd
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult males or females above 18 years of age; * Pseudophakic patients implanted with 640AD monofocal IOLs (implanted between December 2021 - December 2022); * Diagnosis of cataract and/or ametropia (hyperopia, myopia); * Subject who has signed an informed consent form. * Patients who have participated in all visits that are subject to retrospective data collection.

Exclusion criteria

* Patients who are not targeted to emmetropia ( outside -0,5 and 0,5 D) * Patients with the following condition(s) at the time of the baseline visit: * Corneal astigmatism \> 1.5 D * Uncontrolled diabetic retinopathy * Iris neovascularization * Congenital eye abnormality * Uncontrolled glaucoma * Pseudoexfoliation syndrome * Amblyopia * Uveitis * AMD (advanced AMD) * Retinal detachment * Prior ocular surgery in personal medical history * Previous laser treatment * Corneal diseases * Severe retinal diseases (dystrophy, degeneration) * High myopia * Inadequate visualization of the fundus on preoperative examination * Patients deemed by the clinical investigator because of any systemic disease * Pregnancy * Eye trauma in medical history * Current use of systemic steroids or topical ocular medication * Patients with any eye condition that could affect vision in the opinion of the investigator at the time of the 12-month follow-up: (corneal ectasia, retinal diseases, glaucoma, uveitis, dry eye or amblyopia, etc.)

Design outcomes

Primary

MeasureTime frameDescription
Monocular corrected distance visual acuity (CDVA)12 months postoperativelyTo compare monocular corrected distance visual acuity (CDVA) between 12 months postoperative and preoperative results.

Secondary

MeasureTime frameDescription
Monocular uncorrected distance visual acuity (UDVA)12 months postoperativelyTo compare monocular uncorrected distance visual acuity (UDVA) at 12 months postoperative and preoperative status.
UDVA and CDVA12 months postoperativelyTo compare percentage of eyes that achieve monocular UDVA and monocular CDVA within logMAR 0.0 or 0.3 at 12 months postoperative and preoperative status.
Manifest residual refraction12 months postoperativelyTo compare residual SPH at 12 months postoperative and preoperative status. (Residual CYL and axis are not applicable, as it is a monofocal IOL, that does not correct astigmatism)
Patient satisfaction12 months postoperativelyVisual Function Questionnaire 25 (National Eye Institute) is used to evaluate overall satisfaction, subjective perception of colour perception and scotopic vision at 12 months postoperatively. The results are evaluated according to the official evaluation guide.

Other

MeasureTime frameDescription
Safety outcome - Complications of IOL implantationMonth12 postoperativelyComplications of IOL implantation * Posterior capsular opacification (PCO) * Opacification, IOL discoloration
Safety outcome - Postoperative complicationsMonth1 postoperativelyPostoperative complications of cataract surgery * Cystoid macular oedema * Iris abnormalities * Corneal oedema * Wound leak or rupture * IOL dislocation, removal, or exchange * Inflammation (Endophthalmitis, anterior chamber cells, anterior chamber flare, hypopyon) * Retinal tear, break, or detachment * Persistent iritis * Elevated intraocular pressure * Pupillary block * Cornea status
Safety outcome - Intraoperative complicationsDay1 postoperativelyIntraoperative complications of cataract surgery * Posterior capsular or zonular rupture * Vitreous loss/anterior vitrectomy or aspiration * Iris/ciliary body injury * Loss of nuclear material into vitreous * Suprachoroidal haemorrhage * Retrobulbar haemorrhage

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026